SBIR/STTR Research Award

Dysbiotic Rebalancing with S. epidermidis Fermentation in Acne Vulgaris

Award identifier 83c7e54c462818866e16740f8b2ee8450e862e5f30b3034d3e5b82ec2b2320e0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$150,000

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Surface Bioadvances, Inc.
Proposal award date
2015-09-08
Contract end date
2016-08-31
UEI
QAMJN77P4VM8
Solicitation number
PA14-072
Topic code
NIAMS

Research abstract

DESCRIPTION provided by applicant Dysbiosis refers to a condition with microbial imbalances within the human microbiome Yogurts are the best examples of using fermenting gut bacteria to rebalance the gut dysbiosis Our results demonstrate for the first time that Staphylococcus epidermidis S epidermidis a commensal bacterium of the human skin functions as a probiotic microorganism that employs fermentation to restrain the over growth of Propionibacterium acnes a skin opportunistic bacterium associated with acne vulgaris Like microbial competition in a ripening fruit we envision that S epidermidis and P acnes within an acne microenvironment compete with each other for the same carbon source of fermentation To intensify the ability of S epidermidis to andquot beatandquot out its competitor P acnes the a lactose monohydrate ALM a selective fermentation initiator will be used to exclusively trigger the fermentation of S epidermidis The concept of using S epidermidis fermentation against P acnes will be applied for {development of post antibiotic adjuvant therapy for treatment of acne vulgairs A short chain fatty acid SCFA with antimicrobial activity in the fermentative metabolites of S epidermidis will be formulated with clindamycin a commonly prescribed topical antibiotic for acne vulgaris The effects of SCFA on the suppression of P acnes growth and reduction of required doses of clindamycin will be investigated {We have recently obtained acne biopsies in collaboration with Dr Tissa R Hata a Director of the Dermatology Clinical Trials Unit at University of California San Diego UCSD These acne biopsies have been used to establish ex vivo acne explants The effectiveness of SCFA or the SCFA clindamycin combination on suppression of P acnes growth and reduction of pro inflammatory cytokines will be tested by using ex vivo acne explants } Three Specific Aims are proposed to validate our hypothesis In Specific Aim we will identify a SCFA for selectively eliminating P acnes without inhibiting S epidermidis {measure the concentrations of SCFAs in human ex vivo acne explants and determine an effective concentration of SCFA for suppression of P acnes growth In Specific Aim we will validate the essential role of probiotic S epidermidis in the inhibitio of P acnes growth in acne lesions compare the potency of SCFA against P acnes to that of antibiotic and develop SCFA as an antibiotic adjuvant In Specific Aim we will explore the possible disruptive effects of SCFA on skin commensals and examine the cytotoxicities of SCFA with without clindamycin to skin cells } In addition to developing a novel acne therapeutic { SCFA as post antibiotic adjuvant therapy } we emphasize the notion that {combination of antibiotics with probiotic derived metabolites may greatly reduce the side effects of antibiotics for treatment of acne vulgaris } PUBLIC HEALTH RELEVANCE Dysbiotic acne vulgaris is associated with the over growth of Propionibacterium acnes P acnes Our results have demonstrated that Staphylococcus epidermidis S epidermidis a Gram positive bacterium co existed with P acnes in an acne lesion can exploit the carbohydrate fermentation to inhibit the growth of P acnes Our approach here is to selectively amplify the fermentation activity of S epidermidis to rebalance the acne dysbiosis {and develop short chain fatty acids main ferment metabolites as post antibiotic adjuvant therapy for treatment of acne vulgaris }

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2013–2017). Reported award amounts total $525,000. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.